Clinical trials
Sickle Cell clinical trials
Below are recruiting sickle cell clinical trials, each written for real people, not researchers. We’re tracking 172 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT03327428Recruiting
Registry study for people with sickle cell disease
This study is a registry that collects information about people living with sickle cell disease. It may help researchers better understand sickle cell types in Germany, Austria, and Switzerland and support future research and care.
Heidelberg, Baden-WurttembergAges birth–100 years - NCT07000747Recruiting
Dengue and sickle cell disease study
This study looks at how severe dengue fever affects people with sickle cell disease. It aims to understand why some people with sickle cell get very sick from dengue and how their cells react.
Pointe-à-PitreAges 6–25 - NCT02098863Recruiting
Research program for people with sickle cell disease on hydroxyurea
This trial program studies sickle cell disease and how treatment works, especially for people who are already taking hydroxyurea at a stable, maximum tolerated dose. It may help researchers better understand treatment effects and side effects in real patients.
Peoria, IllinoisAges Any age - NCT07800247Recruiting
Sickle cell disease registry for young patients
This study collects information about children, teens, and young adults with sickle cell disease to better understand the condition in Egypt. It may help improve care and treatments for people with sickle cell disease.
CairoAges Up to 39 years - NCT06757829Recruiting
Lung function in sickle cell: testing Acu-TENS therapy
This study tests if a gentle electrical nerve stimulation treatment (called Acu-TENS) can help improve your lung function. It's for people with sickle cell disease who are not currently in pain or have other major health issues.
Dokki, Giza GovernorateAges 20–50 - NCT06699849RecruitingPhase 2
CSL889 for sickle cell pain crisis
This trial tests a new medicine, CSL889, for people with sickle cell disease who are currently having a pain crisis (vaso-occlusive crisis). The goal is to see if it safely helps reduce the pain and speed recovery.
Oakland, CaliforniaAges 12 years+ - NCT02824471Recruiting
Testing a chip technology for sickle cell samples
This trial tests a “biochip” device using samples from people with sickle cell disease. If it works, it may help doctors study sickle cell biology more accurately using patient samples.
Cleveland, OhioAges 12 years+ - NCT07432867RecruitingPhase 1/Phase 2
Gene therapy for severe sickle cell disease in teens and adults
This trial tests a new gene therapy for sickle cell disease. It uses your own blood stem cells (collected from bone marrow) that are modified in a lab to help produce healthy red blood cells, then given back to you after a short chemotherapy. The goal is to reduce or stop severe complications like pain crises and lung problems.
Paris, Île-de-France RegionAges 12–35 - NCT07015684RecruitingPhase 1
Radioactive antibody and transplant for advanced sickle cell disease
This trial tests a radioactive antibody (131I-apamistamab) as part of conditioning before a stem cell transplant from a matched sibling donor. It aims to make the transplant safer and more effective for people with severe sickle cell disease.
New York, New YorkAges 12–50 - NCT05373771Recruiting
Care plan for sickle cell pain crises in the ER
This trial studies an approach to improve care during emergency room visits for uncomplicated sickle cell pain crises. It may help by guiding how pain is treated in the ER and tracking outcomes for people with sickle cell disease.
Milwaukee, WisconsinAges Up to 18 years - NCT07369024RecruitingPhase 2
Study of low-dose ketamine for sickle cell pain crisis
This study tests whether a low-dose of ketamine (a pain medicine) can help children and young adults with sickle cell disease who are in a pain crisis. It aims to provide better pain relief while avoiding some side effects of standard painkillers.
Torrance, CaliforniaAges 5–20 - NCT07274254RecruitingPhase 3
Lidocaine for sickle cell pain crisis in intensive care
This trial tests whether a numbing medicine (lidocaine) given through a vein can help reduce the amount of strong painkillers (morphine or oxycodone) needed for a sickle cell pain crisis or acute chest syndrome. It aims to ease pain and possibly lower side effects from opioids.
BordeauxAges 18 years+ - NCT04628585Enrolling by invitation
Follow-up for people with sickle cell treated with gene therapy
This study is a long-term follow-up for people who already received gene therapy for sickle cell disease in a specific sponsor’s clinical trial. It helps researchers watch for long-term safety and outcomes over time.
Birmingham, AlabamaAges 2–53 - NCT04208529Enrolling by invitationPhase 3
Long-term follow-up after receiving CTX001 infusion
This study follows people for a long time after they received CTX001 in an earlier (parent) study. It helps researchers learn about long-term safety and outcomes of the treatment.
Palo Alto, CaliforniaAges 2 years+ - NCT06318143Recruiting
Increasing use of hydroxyurea for sickle cell in Nigeria
This study aims to help more people with sickle cell disease in Nigeria start taking hydroxyurea, a medicine that can prevent pain crises and other complications. It will work with clinics to make it easier for patients to get and stay on this treatment.
AbujaAges 1 year+ - NCT05953584RecruitingPhase 2
Etavopivat for preventing stroke risk in sickle cell children
This trial studies etavopivat to see if it can improve blood-flow measurements in the brain that predict future stroke risk in children with sickle cell disease. If you qualify, you would take the study medicine and be monitored with brain blood-flow testing.
Raipur, ChhattisgarhAges 12–16 - NCT06439082RecruitingPhase 3
Crizanlizumab for sickle cell pain crises
This trial tests whether crizanlizumab can reduce painful sickle cell crises (called vaso-occlusive crises or VOCs) in people with sickle cell disease who have frequent crises. It may be an option for those who still have crises despite current treatments.
Birmingham, AlabamaAges 12–100 - NCT06260891RecruitingPhase 2
Zinc study for sickle cell disease and bone health
This study tests if taking zinc supplements can improve bone health in people with sickle cell disease. It's for those with certain types of sickle cell disease (SS or S-Beta zero thalassemia) who are not on chronic transfusions or zinc supplements.
Oakland, CaliforniaAges 15–40 - NCT05383911Recruiting
Sickle cell care plan choices for teens and young adults
This trial tests a way to help teens and young adults with sickle cell disease (SCD) and their caregivers actively take part in treatment decisions. It focuses on improving shared decision-making through interviews and a partner-centered approach.
Wilmington, DelawareAges 15 years+ - NCT04416178Recruiting
Survey and interviews for families affected by sickle cell disease
This study collects feedback through surveys, interviews, and focus groups from people affected by sickle cell disease. Your input helps the research team improve how genomic and gene-therapy information and needs are understood for patients and caregivers.
Memphis, TennesseeAges 13 years+ - NCT07175051RecruitingPhase 2
Testing a kidney-protecting drug in sickle cell disease
This study tests whether empagliflozin, a medicine that protects the kidneys in people with diabetes, can also protect the kidneys in people with sickle cell disease. The goal is to see if it can reduce protein in the urine, which is a sign of kidney stress.
Chicago, IllinoisAges 18–60 - NCT06735625Recruiting
AHSP as a biomarker for sickle cell disease
This study looks at a substance in the blood called AHSP to see if it can help track sickle cell disease. It compares people with sickle cell disease (SS or Sβ0 type) to people without it, to better understand the condition.
Saint-DenisAges 3 years+ - NCT06363760Enrolling by invitation
Long-term follow-up after EDIT-301 gene therapy
This long-term follow-up study monitors people with sickle cell disease or transfusion-dependent beta-thalassemia who have already received the gene-editing therapy EDIT-301. It helps researchers understand how safe and effective the treatment is over time.
Oakland, CaliforniaAges 12–50 - NCT04657822RecruitingPhase 4
Crizanlizumab rollover study for people with sickle cell disease
This study lets people with sickle cell disease who already finished a Novartis crizanlizumab trial continue treatment under a rollover plan. It’s designed for participants who benefited from crizanlizumab and completed the earlier study schedule without major ongoing side effects.
Birmingham, AlabamaAges 6 months–100 years
Hear when a new Sickle Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for sickle cell?
- Yes. Clin2 currently lists 172 recruiting sickle cell studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a sickle cell trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a sickle cell trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.